The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

According to the Ministry of Health and Welfare's National Health and Nutrition Survey, the prevalence of diabetes in 2023 ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only ...

The goal of the partnership between Topcon and Pangaea is to “accelerate the application of Pangaea’s clinically validated AI ...

Telangiectatic capillaries may have potential clinical relevance for diagnosis and treatment of diabetic macular edema.

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...